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Ifosfamide is an alkylating agent used in the treatment of many
solid tumours. Its use may be limited by specific side effects. One
of the most serious of these is central nervous system (CNS)
depression known as ifosfamide-induced encephalopathy. The
clinical picture can range from mild somnolence or agitation over
confusion or hallucinations to deep coma. Until recently, there was
no effective treatment for this complication and when it occurred
ifosfamide administration had to be discontinued. There have been
some sporadic reports of patients with ifosfamide-induced
encephalopathy being successfully treated with methylene blue
(Küpfer et al, 1994; Zulian et al, 1995; Ferrero et al, 1995;
Demandt and Wandt, 1996; Alonso et al, 1996). In this paper we
present our experience with methylene blue (MB) in the treatment
and prevention of ifosfamide-induced encephalopathy and give a
review of the literature.
PATIENTS AND METHODS
The files of all patients treated with ifosfamide- containing regi-
mens between 1993 and 1997 were studied retrospectively.
Ifosfamide was used both as single agent or in combination
chemotherapy in doses ranging from 3 to 5g m–2 every 3 weeks
when used in combination therapy and up to 12g m–2 every 4
weeks when used as single agent.
Ifosfamide was administered in different infusion schemes
varying from fractionated, 1-h infusions on 3 consecutive days in
the combination treatments to a continuous 72-h infusion in the
high dose schedules. All patients received standard prehydration
with normal saline. Haematological and non-haematological toxi-
cities were classified according to the National Cancer Institute –
Common Toxicity Criteria (NCI-CTC) (Van Tongelen, 1994).
Encephalopathy grading is shown in Table 1. Neurocortical toxi-
city was graded as significant when it was at least grade 2.
At that time routine electroencephalogram was not performed
for this indication at our department.
The time to recovery from the encephalopathy in the group of
patients treated with methylene blue and in the group without
treatment was recorded.
RESULTS
In total, 52 patients were treated with ifosfamide. Most of these
patients had sarcoma (32%), lung (17%) or cervical carcinoma
(13%). Twelve patients (23%) developed NCI-CTC neurotoxicity
grade 2 or more (Table 2). The infusion of ifosfamide was not
stopped in any of these patients. When compared to the 40 patients
without neurotoxicity, there was no difference in renal function
(data not shown). There were fewer patients with pelvic localiza-
tion of disease in the group who had neurotoxicity (16% vs 42%).
Eight patients were treated with MB in a dose of 6 ´50mg
day–1 intravenously (i.v.), and four were not treated because the
attending physician did not judge the situation, although grade 2 or
more neurotoxicity, as severe. Methylene blue was started imme-
diately upon clinical diagnosis.
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Correspondence to:JB VermorkenFour of eight patients treated with MB recovered completely
within the first 24 h, three of these within 12 h. One of them recov-
ered within 1 h of a grade 4 neurotoxicity after the administration
of MB.
Two patients had incomplete recovery after 24 h but recovered
fully after 48 h. Two patients recovered after 72 h. The mental
status of the patients without MB became normal after 48 h.
Three patients received prophylactic MB in a dose of 4 ´ 50 mg
day–1 i.v. for the next courses. Two of them developed an
encephalopathy of lower grade and one had no subsequent
evidence of neurotoxicity.
DISCUSSION
Ifosfamide is a prodrug metabolized by cytochrome p450 to its
active alkylating agents, 4-hydroxy-ifosfamide and isofosforamide
mustard (Kaijser et al, 1994). Other non-alkylating metabolites are
being formed, which may be responsible for the toxicity of
ifosfamide (Kurowski et al, 1991).
The likelihood of ifosfamide-induced encephalopathy depends
on the route of administration (Cerny et al, 1990). It is more
common after oral than after i.v. administration. After i.v. adminis-
tration, it occurs more frequently with a short infusion time. It is
therefore generally accepted to give ifosfamide as a protracted or
fractionated infusion.
The exact pathophysiological mechanisms responsible for the
development of ifosfamide-induced encephalopathy are not
known. Küpfer et al (1996) presented possible pathways by which
ifosfamide metabolites can induce neurotoxicity. These hypo-
theses were based on the finding of glutaric acid and sarcosine in
the urine of a patient with ifosfamide-induced encephalopathy.
The same products are also found in the urine of patients with
congenital glutaric aciduria. In these patients a metabolic dysfunc-
tion is caused by the absence of glutaryl CoA (type 1) or by a lack
of electron transferring flavoproteins in the mitochondrial respira-
tory chain (type 2). Further investigations showed a relation
between glutaric aciduria and chloroethylamine but not with any
of the other metabolites of ifosfamide. This led to the conclusion
that chloroethylamine may be the principal neurotoxic metabolite
of ifosfamide.
Chloroethylamine conjugates with cystein, thus forming thia-
lysine, which can be metabolized to thialysine ketimine. The latter
can inhibit the electron-binding flavoproteins in the mitochondrial
respiratory chain. Thialysine ketimine could have CNS effects on
its own. The inhibition of the mitochondrial respiratory chain may
also lead to a disturbance of the intracellular NAD/NADH balance
with the accumulation of NADH. This in turn prevents the
dehydrogenation of aldehydes, such as the ifosfamide metabolite
chloracetaldehyde, which need NAD for their oxidation. Chlor-
acetaldehyde is a potential neurotoxic substance. It is closely
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Table 1 NCI common toxicity criteria; neurocortical toxicity
Grade
01 2 3 4
Symptoms None Mild Moderate Severe Coma,
somnolence somnolence or somnolence, seizures,
or agitation agitation agitation, toxic
confusion, psychosis
disorientation
or
hallucinations
Table 2 Results
Patient Diagnosis Toxicity Dose Infusion Methylene Time of Time to Prophylaxis Second
no. grade (g m–2 day–1) time blue first recovery (mg day–1) event
(h) symptom (h)
(mg day–1 (day)
1 NSCLC 2 1.5 g m–2 days 1–3 1 3 48
2 Liposarcoma 3 4 g m–2 days 1–3 24 5 48
3 Ovarian carcinoma 2 5 g m–2 24 1 48
4 Chondrosarcoma 2 4.7 g m–2 days 1–3 24 4 48
5 Synovial sarcoma 4 5 g m–2 24 6 ´ 50 2 12
6 Small-cell carcinoma 3 4 g m–2 24 6 ´ 50 8 12
7 Stromal sarcoma 3 3.2 g m–2 days 1–3 24 6 ´ 50 4 12
8 Neuro-endocrine tumour 2 1.5 g m–2 days 1–3 1 6 ´ 50 3 24
9 Malignant schwannoma 3 4 g m–2 days 1–3 24 6 ´ 50 3 48 4 ´ 50 grade 2
10 Rhabdomyosarcoma 3 2.5 g m–2 day 1 12 6 ´ 50 2 48
3g  m –2 day 2
3.5 g m–2 day 3
11 Angiosarcoma 3 4 g m–2 days 1–3 24 6 ´ 50 3 72 4 ´ 50 grade 0
12 Cystosarcoma 3 4 g m–2 days 1–3 24 6 ´ 50 3 72 4 ´ 50 grade 2
phyloidesrelated to chloralhydrate, a known hypnotic, and to acetaldehyde
which is the neurotoxic metabolite of ethanol (Pratt et al, 1990).
Another important pathway may be mediated by monoamine-
oxidase in the extrahepatic tissues and in plasma by which chlor-
acetaldehyde can be formed (Aeschlimann et al, 1996).
Methylene blue counteracts some of these metabolic pathways
(Küpfer et al, 1996). It may act as an alternative electron acceptor,
replacing the inhibited flavoproteins and thus restoring the mito-
chondrial respiratory chain (Harpey et al, 1986). It may also
oxidate NADH, allowing dehydrogenation of the aldehydes
(Hrushesky et al, 1985). It has also been found that MB may
inhibit the plasma and extrahepatic monoamine oxidases
(Aeschlimann et al, 1996). This may explain the preventive action
of MB. To our knowledge, there are no known interactions with
the pharmacokinetics of ifosfamide (Aeschlimann, 1998).
In our retrospective study, NCI-CTC neurotoxicity grade was
lower during further ifosfamide treatment in the MB-treated group
versus the untreated group of patients with ifosfamide-induced
CNS effects. However, the numbers were small and the study was
not randomized. Furthermore, because it was retrospective based
on the patients’ files, recovery times were only recorded in the
daily progress notes and the shortest time recorded was 24 h with
the exception of a few patients where multiple daily entries were
made in the patient’s medical file. The relatively high incidence of
ifosfamide encephalopathy is probably due to the ifosfamide
schedules used.
The literature mentions only six patients with ifosfamide-
induced encephalopathy, which have been treated with MB,
usually with spectacular results (Table 3). The first to present such
a case was Küpfer et al (1994). Their patient recovered 30 min
after administration of 50 mg of MB. They advised the prophy-
lactic use of 3–4 ´ 50 mg day–1 of MB. Later there were publica-
tions by Zulian et al (1995), Ferrero et al (1995) and Demandt and
Wandt (1996). Alonso et al (1996) advised the same dose of MB
that we used in our study, based on their observations after admin-
istration of 60 mg of MB. As we observed, even with the use of
MB there may be a long recovery time. Koschuth et al (1996)
presented a patient with a recovery of ifosfamide-induced
encephalopathy 8 days after treatment with MB.
There are four studies on the duration of ifosfamide-induced
encephalopathy in patients without a treatment with MB. They
reported recovery times up to 29 days with an occasional fatal
outcome. DiMaggio et al (1994) documented recovery times
ranging from 2 to 7 days, Merimsky et al (1992) from 3 to 7 days
and Curtin et al (1991) up to 13 days. Watkin et al (1989) even
mentioned two patients in whom the encephalopathy lasted for
more than 20 days.
There seems to be an advantage in using MB as a mean of short-
ening the duration of, or as a mean of preventing ifosfamide-
induced encephalopathy, as was seen in our patients. Therefore,
based on our experience and the available literature, we advise the
intravenous use of MB in a dose of 6 ´ 50 mg day–1 for treatment
and 4 ´ 50 mg day–1 either i.v. or orally for secondary prophylaxis
of ifosfamide-induced encephalopathy.
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